Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cardiovascular

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1544039

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1544039

Angina Pectoris Drugs

PUBLISHED:
PAGES: 196 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Angina Pectoris Drugs Market to Reach US$19.7 Billion by 2030

The global market for Angina Pectoris Drugs estimated at US$14.5 Billion in the year 2023, is expected to reach US$19.7 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2023-2030. Beta Blockers, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$9.6 Billion by the end of the analysis period. Growth in the Calcium Channel Blockers segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.0 Billion While China is Forecast to Grow at 4.3% CAGR

The Angina Pectoris Drugs market in the U.S. is estimated at US$4.0 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.1 Billion by the year 2030 trailing a CAGR of 4.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Angina Pectoris Drugs Market - Key Trends and Drivers Summarized

Why Are Angina Pectoris Drugs Vital in Cardiovascular Care?

Angina pectoris, a condition characterized by chest pain due to reduced blood flow to the heart, remains a significant concern in cardiovascular care. Effective management of angina pectoris is critical to improving patient outcomes and preventing more severe cardiac events. Angina pectoris drugs, including nitrates, beta-blockers, calcium channel blockers, and antiplatelet agents, play an essential role in alleviating symptoms, enhancing quality of life, and reducing the risk of heart attacks. The availability of these drugs in various formulations—such as tablets, capsules, and injectables—ensures that treatment can be tailored to individual patient needs. As cardiovascular diseases continue to be the leading cause of mortality globally, the importance of these drugs in clinical practice cannot be overstated.

How Are Technological Advancements Influencing the Angina Pectoris Drugs Market?

Technological advancements are significantly shaping the landscape of the angina pectoris drugs market. Innovations in drug formulation and delivery systems are enhancing the efficacy and safety profiles of these medications. For instance, the development of extended-release formulations and transdermal patches allows for more consistent drug delivery and better patient adherence. Additionally, advancements in pharmaceutical research, particularly in the fields of genomics and personalized medicine, are paving the way for targeted therapies that address the specific genetic and molecular profiles of patients. This approach not only improves treatment outcomes but also minimizes adverse effects. The integration of digital health tools, such as mobile apps for medication management and remote monitoring, further enhances patient compliance and enables real-time adjustments to treatment plans.

Why Is Patient-Centric Care Central to Angina Pectoris Treatment Strategies?

Patient-centric care is increasingly becoming the cornerstone of angina pectoris treatment strategies. As healthcare systems shift towards more personalized and preventive approaches, there is a growing emphasis on understanding patient-specific factors that influence the effectiveness of treatment. Lifestyle modifications, risk factor management, and patient education are integral components of a comprehensive treatment plan. Healthcare providers are now leveraging digital tools to educate patients about their condition, track their progress, and remind them to take their medications. This holistic approach not only improves patient outcomes but also enhances the overall experience, leading to higher satisfaction rates. Moreover, the focus on patient adherence and compliance is critical in ensuring the long-term success of angina pectoris management, as consistent medication use is vital in preventing recurrent episodes and complications.

What Factors Are Driving Growth in the Angina Pectoris Drugs Market?

The growth in the angina pectoris drugs market is driven by several factors related to technological advancements, end-use applications, and evolving healthcare practices. The increasing prevalence of cardiovascular diseases and the aging global population are major contributors to market expansion, as the incidence of angina pectoris rises with age. Technological innovations in drug development, including the creation of more effective and safer formulations, are propelling the adoption of new treatments. The trend towards personalized medicine, supported by advancements in biomarker research, is strengthening the business case for targeted angina pectoris therapies. Additionally, the integration of digital health tools into treatment plans is generating demand for comprehensive management solutions. Rising healthcare expenditure and improved insurance coverage are further facilitating access to these medications. Moreover, the growing focus on preventive cardiovascular care and the shift towards outpatient treatments are expanding the addressable market for angina pectoris drugs. These factors collectively drive the robust growth of the angina pectoris drugs market, highlighting the ongoing need for innovative and effective therapeutic solutions.

Select Competitors (Total 46 Featured) -

  • Amgen, Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Sanofi SA
Show more
Product Code: MCP10288

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Angina Pectoris Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Prevalence of Cardiovascular Diseases Throws the Spotlight on Angina Pectoris Drugs
    • Advances in Drug Formulation and Delivery Systems Propel Growth in the Angina Pectoris Market
    • Development of Personalized Medicine Strengthens Business Case for Advanced Angina Pectoris Treatments
    • Shift Towards Preventive Cardiovascular Care Impacts the Angina Pectoris Drugs Market
    • Integration of Digital Health Tools in Treatment Plans Generates Demand for Comprehensive Angina Management
    • Trends in Polypharmacy and Combination Therapies Propel Growth in the Angina Pectoris Drugs Market
    • Evolution of Generic Drugs and Biosimilars Expands Addressable Market for Angina Pectoris Medications
    • Advances in Biomarker Research Strengthen Business Case for Targeted Angina Pectoris Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Angina Pectoris Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Angina Pectoris Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Angina Pectoris Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Beta Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Calcium Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for ACE Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Nitrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Nitrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Nitrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Anti-Platelets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Anti-Platelets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Anti-Platelets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Therapeutic Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • JAPAN
    • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • CHINA
    • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: China Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: China 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • EUROPE
    • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Angina Pectoris Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Angina Pectoris Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Europe 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • FRANCE
    • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 41: France Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: France Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: France 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • GERMANY
    • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Germany Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Germany 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 47: Italy Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Italy Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Italy 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: UK Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: UK 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of Europe 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 59: Rest of World Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Rest of World Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Rest of World 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!